tadalafil + tadalafil + placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroparesis
Conditions
Gastroparesis
Trial Timeline
Feb 1, 2003 → Sep 1, 2003
NCT ID
NCT00050609About tadalafil + tadalafil + placebo
tadalafil + tadalafil + placebo is a phase 2 stage product being developed by Eli Lilly for Gastroparesis. The current trial status is completed. This product is registered under clinical trial identifier NCT00050609. Target conditions include Gastroparesis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00547183 | Phase 3 | Completed |
| NCT00547573 | Phase 3 | Completed |
| NCT00050609 | Phase 2 | Completed |
Competing Products
19 competing products in Gastroparesis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Granisetron | Kyowa Kirin | Phase 2 | 52 |
| tadalafil | Eli Lilly | Approved | 85 |
| Mosapride + domperidone | Sumitomo Pharma | Approved | 85 |
| Cisapride + Placebo | Johnson & Johnson | Approved | 85 |
| Cisapride + Placebo | Johnson & Johnson | Approved | 85 |
| Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet | AstraZeneca | Phase 2 | 52 |
| Sitagliptin + Placebo | Merck | Phase 1 | 33 |
| Tegaserod | Novartis | Approved | 85 |
| Reglan ODT | UCB | Pre-clinical | 20 |
| Hemin + Albumin | Recordati | Phase 2 | 49 |
| CNSA-001 + Placebo | PTC Therapeutics | Phase 2 | 49 |
| Immediate-release omeprazole + Delayed-release omeprazole | Bausch Health | Approved | 80 |
| Velusetrag + Placebo | Theravance Biopharma | Phase 2 | 47 |
| velusetrag dose 1 + velusetrag dose 2 + velusetrag dose 3 + placebo | Theravance Biopharma | Phase 2 | 47 |
| IW-9179 + Matching Placebo | Ironwood Pharmaceuticals | Phase 2 | 44 |
| VLY-686 (Tradipitant) | Vanda Pharmaceuticals | Phase 2 | 44 |
| Tradipitant | Vanda Pharmaceuticals | Phase 3 | 69 |
| Tradipitant | Vanda Pharmaceuticals | Pre-clinical | 15 |
| Tradipitant + Placebo + Open Label Tradipitant | Vanda Pharmaceuticals | Phase 3 | 69 |